A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor

A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor

Standard treatment for metastatic hormone positive (HR+) breast cancer includes a combination of a CDK4/6 inhibitor and antiestrogen therapy. Despite durable responses, eventual endocrine resistance results in disease progression. The Src/Abl pathway has been shown to mediate endocrine resistance in...

Full description

Bibliographic Details
Main Authors: Tina Roy, Elizabeth Barrows, Candace Mainor, Julie Collins, Filipa Lynce, Claudine Isaacs, Paula R. Pohlmann
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Contemporary Clinical Trials Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S245186542300056X

Internet

http://www.sciencedirect.com/science/article/pii/S245186542300056X

Similar Items